Thanks, Larry. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls excluded the impact of any FX gains or losses and assumed an effective tax rate of 25%. So accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. Additionally, the financial results for the first quarter of 2026 includes a charge of $3.7 million for noncash stock compensation expense associated with the future vesting of performance shares for certain employees who have reached eligible retirement age. We also recorded $600,000 of additional costs associated with exiting certain facilities as we continue to optimize our global footprint. The comparison periods for the first and fourth quarter of 2025 also include items that were discussed in those calls and highlighted in our earnings release for those periods. These items have also been excluded from the discussion of the financial results today. You can find a summary of those items in the tables attached to our press release for the first quarter of 2026. Now looking at the income statement. Revenue was $121.8 million in the first quarter, down 12% compared to the prior quarter and down 1% year-over-year. Core Lab will typically experience a seasonal decline in revenue from the fourth quarter to the first quarter of each year. However, as Larry mentioned, in the first quarter of 2026 was also negatively impacted by the escalation of the conflict in the Middle East along with severe weather events in North America and Europe. Of this revenue, service revenue, which is more international, was $94.3 million for the quarter, down 12% sequentially and 1% year-over-year. Our service revenue associated with crude assay services and regional studies continue to be impacted by the geopolitical conflicts in Russia, Ukraine, but particularly in the Middle East this quarter. Additionally, severe weather across North America, Europe and the Mediterranean region negatively impacted certain laboratory operations and disrupted client activity this quarter. Offsetting some of the decline this quarter, we continue to see increased demand for our well completion diagnostic services, particularly in the Gulf of Mexico. Product sales, which are more equally tied to North America and international activity were $27.5 million for the quarter and were down 12% from last quarter and down 3% year-over-year. Our international product sales are typically larger bulk orders and can vary from 1 quarter to another and were down sequentially in the first quarter of 2026. The decrease in product sales this quarter when compared to the fourth quarter of 2025 was partially offset by a higher level of product sales in the U.S. Moving on to cost of services, ex items for the quarter was 81% of service revenue, which increased from 75% in the prior quarter and 77% last year. The sequential increase was primarily caused by the conflict in the Middle East, which resulted in a sharp decrease in revenue as the -- and our clients were forced to suspend operations. As discussed in our previous calls, the service side of our business has been more impacted by the geopolitical conflicts and expanded sanctions, the volatility in crude oil prices and more recently, the geopolitical conflict in the Middle East caused disruptions to both our operations in the region and demand for crude assay services tied to the trading and maritime movement of crude oil and derived products. The company will continue to manage its cost structure as effectively as we can through these temporary disruptions in certain regions. Cost of sales ex items in the first quarter was 94% of revenue, which is relatively flat compared to last quarter and was 91% last year. The company continues to face challenges with increased costs for raw materials and logistics, some of which we've had to absorb. Despite these challenges, we remain focused on improving cost efficiencies and anticipate the manufacturing absorption rate in future quarters will be in line with projected product sales. G&A ex items for the quarter was $11 million, up a little from $10.6 million in the prior quarter. For 2026, we expect G&A ex-items to be approximately $42 million to $45 million. It is also important to note that 100% of our corporate G&A expenses are allocated and absorbed into the financial performance of the reported segments. Depreciation for the quarter was $3.8 million and increased slightly compared to $3.7 million in the last quarter and the first quarter of last year. EBIT ex items for the quarter was $6.6 million, down from $15.7 million last quarter, yielding an EBIT margin of over 5%. Our EBIT for the quarter on a GAAP basis was $1.9 million. Interest expense of $2.9 million for the first quarter increased from $2.6 million in the prior quarter and the same quarter in the prior year. As mentioned last quarter, the increase in the interest expense is associated with the higher interest rate on the new term loan under our credit facility, which was used to retire $45 million of senior notes in January 2026. Income tax expense and an effective tax rate of 25% and ex items was $900,000 for the quarter. On a GAAP basis, we recorded a tax benefit of $300,000 for the quarter. Net income ex items for the quarter was $2.7 million, down 72% sequentially and down 59% from first quarter of last year. On a GAAP basis, we had a net loss of $800,000 for the quarter. Earnings per diluted share ex items was $0.06 for the quarter compared to $0.21 in the prior quarter and $0.14 in the first quarter of last year. On a GAAP basis, we had a loss per diluted share of $0.02 for the quarter. Turning to the balance sheet. Receivables were $108.3 million and decreased approximately $5.3 million from the prior quarter. Our DSOs for the first quarter were at 74 days, up from 69 days last quarter. The increase in DSOs was primarily driven by the escalation of the conflict in the Middle East, which impacted revenue for the quarter and also slowed collections. We will continue to focus our collection efforts in the affected region and anticipate that our DSO will improve in future quarters. Inventory at March 31, 2026, was $57.8 million, up $3.3 million from last quarter end. Inventory turns for the quarter were 1.8% and down from 2.1% last quarter, which is primarily associated with the decrease in international bulk sales this quarter. And now to the liability side of the balance sheet. Our long-term debt was $117 million as of March 31, 2026, and considering cash of $22.8 million, net debt was $94.2 million, which increased $3.9 million from last quarter. Our leverage ratio is currently at 1.2 compared to 1.1% last quarter. Our debt is currently comprised of our senior notes at $65 million, a term loan of $50 million and $2 million outstanding under our bank credit facility. As stated earlier, in the first quarter, we made a single draw of $50 million on a term loan under our credit facility and retired $45 million of senior notes in January of 26. Looking at cash flow for the first quarter of 2026, Cash flow from operating activities was $4 million and after paying approximately $3.5 million of CapEx for operations, our free cash flow for the quarter was $500,000. As discussed in prior quarters, the capital expenditures associated with rebuilding our U.K. facility, which was damaged by fire are covered by the company's property and casualty insurance and have been excluded in the calculation of free cash flow. The capital expenditures associated with rebuilding the U.K. facility in the first quarter were $1.4 million. Looking ahead to the rest of the year, we will continue our strict capital discipline and asset-light business model with capital expenditures primarily targeted at growth opportunities. Excluding the CapEx associated with rebuilding the U.K. facility, we expect capital expenditures to remain aligned with activity levels and for the full year 2026 to be in the range of $15 million to $18 million. Core Lab's operational leverage continues to provide the ability to grow revenue and profitability with minimal capital requirements. Capital expenditures for the operations has historically ranged from 2% to 4% of revenue even during periods of significant growth. That same level with laboratory infrastructure, intellectual property and leverage exists in the business today. We believe evaluating a company's ability to generate free cash flow and free cash flow yield is an important metric for shareholders when comparing and projecting company's financial results, particularly for those shareholders who utilize discounted cash flow models to assess valuations. I will now turn it over to Gwen for an update on our guidance and outlook.